In a decision rendered on 12 June 2024, the full chamber of the private law division (‘Segunda Seção’) of the Brazilian Superior Court of Justice ruled that state courts may decide on the validity of patents when the validity is put in issue by way of defence in civil proceedings for infringement (EREsp 1.332.417/RS). The…

A case concerning an automated vinification system offers us a glimpse of that rare species of patent litigation: the declaratory non-infringement action. The case demonstrates the need to carefully draft this type of action, as well as the need to choose the right evidence to support declarations that go beyond specific models. This is key…

UPC 252/2023 NanoString v Harvard ACT_551180/2023 (UPC_CFI_252/2023) The UPC’s Munich Central Division has recently issued its decision revoking Harvard’s EP 2794928 B1 (“the Patent”) in DE, NL, and FR, with other EPO member states likely excluded from the decision on commercial grounds having lapsed during opposition proceedings in 2019. The decision is appealable. The NanoString decision…

Co-authored by Rodrigo Mourao and Rhuan Quintanilha The global momentum behind 5G continues to build up as its adoption accelerates. At the 2024 Mobile World Congress (MWC) in Barcelona, GSMA Intelligence reported that, as of early 2024, “261 operators across 101 countries have launched commercial 5G services. The number of 5G connections worldwide reached 1.6…

We have long meant to write something about the need, or the lack thereof, for adapting the description to amended claims. The announcement in the second preliminary opinion of Technical Board of Appeal (TBA) 3.3.04 in T 56/21, suggesting a referral of this question to the Enlarged Board of Appeal, combined with the sole appellant’s…

After Novartis had obtained a preliminary injunction against Pharmathen, it observed that there were still infringing acts being performed. In the first instance, the provisions judge sided with Novartis and ordered that Pharmathen had to pay EUR 7,500,000 as a penalty. On appeal Pharmathen tried to reverse this verdict, but its efforts were in vain….

On 8 October 2024, Mr Justice Meade handed down judgment in BioNTech SE and Pfizer Inc., (together, BioNTech/Pfizer) v CureVac SE. Meade J found CureVac’s patents, relating to split poly(A) tails in mRNA, invalid for obviousness and insufficiency due to (i) lack of plausibility and (ii) because the purported technical effect does not in fact…

On 18 September 2024, the Honourable Justice Jackman, in his capacity as a Deputy President of the Administrative Appeals Tribunal (AAT), granted Sandoz a licence pursuant to section 223(9) of the Patents Act 1990 (Cth) (Act).  In doing so, his Honour set aside an earlier, 2019 decision, in which the Commissioner of Patents (Commissioner) had also…